Authors
Xingyu Lei, Shibing Wang, Weijiao Fan, Yehui Kang, Haohan Chen, Yuqing Lv, Tong Ge, Yuxuan Liu, Luyi Ye, Fei Wu, Yangyang Li, Xiaozhou Mou, Xiang Wang
Published in
Journal of controlled release : official journal of the Controlled Release Society. Pages 115545. Nov 19, 2026. Epub Nov 19, 2026.
Abstract
Oncolytic virus (OV) therapy is clinically administered mainly by intratumoral injection, whereas systemic delivery remains limited by poor tumor tropism and severe side effects. Here we report a virus-concealed tumor-targeting strategy that enables systemic administration of OVs to lung metastases. We first screened and obtained the 4 T1-LUNG cell line, which exhibits high lung metastatic capacity. Enucleation was then used to treat 4 T1-LUNG cells to abolish pathogenicity while preserving other cellular characteristics. The enucleated 4 T1-LUNG cells were subsequently infected with Reovirus to form enucleated 4 T1-LUNG-Reovirus complexes (termed E4L-Rs). This delivery system increases viral payload, owing to the absence of transcriptional machinery and interferon (IFN) signaling, and protects against viral neutralization and clearance in the circulatory system. It also enables lung-specific targeting via the Cxcl12-Cxcr4 and Itgb1-Fak-Src axes, resulting in a more than 320-fold increase in viral accumulation in lung tissue. Upon reaching the lung, E4L-Rs induce immunogenic cell death (ICD) in tumor cells, promoting the expansion of cytotoxic CD8+ T cells and M1 macrophages and converting immunologically 'cold' tumors into 'hot' tumors. The E4L-Rs platform thus offers a promising strategy for oncolytic virus-targeted therapy against tumor metastasis.
PMID:
43057342
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 4
- Comments 0